Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT07565389
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
42
Enrollment
OTHER
Sponsor class
Conditions
Nasopharyngeal Carcinoma (NPC)
Interventions
DRUG:
Ivonescimab 20 mg/kg
Sponsor
National University Hospital, Singapore